Drug guidance
Momelotinib for treating myelofibrosis in patients with moderate to severe anaemia
Condition
Blood and Immune System
Cancer
16 September 2025
-
Published on 16 Sep 2025
Last Updated on 16 Sep 2025
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has not recommended momelotinib for inclusion on the MOH List of Subsidised Drugs for treating myelofibrosis (MF)-related splenomegaly or symptoms in patients with moderate to severe anaemia. This decision was based on momelotinib being unlikely to represent an acceptable use of healthcare resources at the price proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for momelotinib are provided in the Annex.